Compounds > 2-(6-(4-chlorophenoxy)hexyl)oxirane-2-carboxylic acid
Page last updated: 2024-12-04

2-(6-(4-chlorophenoxy)hexyl)oxirane-2-carboxylic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID1231
CHEMBL ID2216791
SCHEMBL ID682291
SCHEMBL ID6260778
MeSH IDM0147842

Synonyms (13)

Synonym
104699-06-1
2-(6-(4-chlorophenoxy)hexyl)oxirane-2-carboxylic acid
2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylic acid
124151-60-6
CHEMBL2216791
4-cphoc
oxiranecarboxylic acid, 2-(6-(4-chlorophenoxy)hexyl)-
b-827-33
b 827-33
SCHEMBL682291
SCHEMBL6260778
2-[6-(4-chlorophenoxy) hexyl]-oxirane carboxylic acid
DTXSID10909136
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID719722Reduction in plasma glucose in 48 hrs fasted pig at 20 mg, iv measured 5 hrs post dose2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719723Reduction in blood 3-OH-butyrate in Wistar rat at 60 mg/kg, iv over 5.5 hrs (Rvb = 1 mM)2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719725Reduction in whole body glucose utilization in Wistar rat at 60 mg/kg, iv over 5.5 hrs2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719724Reduction in glucose carbon recycling in Wistar rat at 60 mg/kg, iv over 5.5 hrs2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719726Reduction in plasma glucose in Wistar rat at 60 mg/kg, iv over 5.5 hrs2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (40.00)18.7374
1990's2 (40.00)18.2507
2000's0 (0.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.53 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.53)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
4-hydroxyphenylglyoxylic acid
4-hydroxyphenylglyoxylic acid: RN given refers to parent cpd. 4-hydroxyphenylglyoxylate : Conjugate base of 4-hydroxyphenylglyoxylic acid.		2.0610phenols
amiodarone
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.. amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.		2.06101-benzofurans;
aromatic ketone;
organoiodine compound;
tertiary amino compound		cardiovascular drug
ciprofibrate
[no description available]		1.9710cyclopropanes;
monocarboxylic acid;
organochlorine compound		antilipemic drug
clofibrate
angiokapsul: contains clofibrate & insoitolnicotinate		1.9710aromatic ether;
ethyl ester;
monochlorobenzenes		anticholesteremic drug;
antilipemic drug;
geroprotector;
PPARalpha agonist
clofibric acid
Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.. clofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate.		1.9710aromatic ether;
monocarboxylic acid;
monochlorobenzenes		anticholesteremic drug;
antilipemic drug;
antineoplastic agent;
herbicide;
marine xenobiotic metabolite;
PPARalpha agonist
perhexiline
Perhexiline: 2-(2,2-Dicyclohexylethyl)piperidine. Coronary vasodilator used especially for angina of effort. It may cause neuropathy and hepatitis.		2.0610piperidinescardiovascular drug
galactose
galactopyranose : The pyranose form of galactose.		1.9710D-galactose;
galactopyranose		Escherichia coli metabolite;
mouse metabolite
trimetazidine
Trimetazidine: A vasodilator used in angina of effort or ischemic heart disease.		2.0610aromatic amine
4-hydroxyphenylglycine, (s)-isomer
L-4-hydroxyphenylglycine : The L-enantiomer of 4-hydroxyphenylglycine.		2.06104-hydroxyphenylglycine
bezafibrate
[no description available]		1.9710aromatic ether;
monocarboxylic acid amide;
monocarboxylic acid;
monochlorobenzenes		antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic
ethyl 2-(5-(4-chlorophenyl)pentyl)oxiran-2-carboxylate
[no description available]		2.0610
octyl glucoside
octyl-beta-D-glucoside: RN given refers to (beta)-isomer. octyl beta-D-glucopyranoside : An beta-D-glucoside in which the anomeric hydrogen of beta-D-glucopyranose is substituted by an octyl group.		1.9810beta-D-glucosideplant metabolite
glucose, (beta-d)-isomer
beta-D-glucose : D-Glucopyranose with beta configuration at the anomeric centre.. (1->4)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->4) linkages.. (1->3)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->3) linkages.		1.9810D-glucopyranoseepitope;
mouse metabolite
methyl 2-tetradecylglycidate
methyl 2-tetradecylglycidate: structure		2.0610
coenzyme a
[no description available]		1.9810adenosine 3',5'-bisphosphatecoenzyme;
Escherichia coli metabolite;
mouse metabolite
3-mercaptopicolinic acid
3-mercaptopicolinic acid: gluconeogenesis inhibitor; may also inhibit ATP-dependentphosphoenolpyruvate carboxykinase		1.9710
emeriamine
emeriamine: derived from fungal metabolite emericedin; structure given in first source		2.0610
malonyl coenzyme a
Malonyl Coenzyme A: A coenzyme A derivative which plays a key role in the fatty acid synthesis in the cytoplasmic and microsomal systems.. omega-carboxyacyl-CoA : An acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with one of the carboxy groups of any alpha,omega-dicarboxylic acid.		1.9810malonyl-CoAsEC 2.3.1.21 (carnitine O-palmitoyltransferase) inhibitor;
Escherichia coli metabolite;
metabolite;
mouse metabolite
etomoxir
[no description available]		2.0610aromatic ether
4-trimethylammonio-3-((tetradecylcarbamoyl)amino)butyrate
[no description available]		2.0610
4-methylene-2-octyl-5-oxofuran-3-carboxylic acid
4-methylene-2-octyl-5-oxofuran-3-carboxylic acid: an anorectic fatty acid synthase inhibitor; structure in first source. (2R,3S)-C75 : A 4-methylidene-2-octyl-5-oxotetrahydrofuran-3-carboxylic acid that has 2R,3S-configuration.		2.06104-methylidene-2-octyl-5-oxotetrahydrofuran-3-carboxylic acid;
gamma-lactone
b 807-27
[no description available]		2.420
ConditionIndicatedRelationship StrengthStudiesTrials
Diabetes Mellitus, Adult-Onset
[description not available]		02.0610
Cardiac Failure
[description not available]		02.0610
Insulin Sensitivity
[description not available]		02.0610
Heart Disease, Ischemic
[description not available]		02.0610
Diabetes Mellitus, Type 2
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.		02.0610
Heart Failure
A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.		02.0610
Insulin Resistance
Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.		02.0610
Myocardial Ischemia
A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).		02.0610
Alloxan Diabetes
[description not available]		01.9710